Effects of Diabetes and Blood Glucose on COVID-19 Mortality: A Retrospective Observational Study - Li, Fei; Cai, Yue; Gao, Chao; Zhou, Lei; Chen, Renjuan; Zhang, Kan; Li, Weiqin; Zhang, Ruining; Zhang, Xijing; Wang, Duolao; Liu, Yi; Tao, Ling (medRxiv, 2021)
OBJECTIVE To investigate the association of diabetes and blood glucose on mortality of patients with Coronavirus Disease 2019 (COVID-19).RESEARCH DESIGN AND METHODS This was a retrospective observational study of all patients with COVID-19 admitted to Huo-Shen-Shan Hospital, Wuhan, China. The hospital was built only for treating COVID-19 and opened on February 5, 2020. The primary endpoint was all-cause mortality during hospitalization.RESULTS Among 2877 hospitalized patients, 13.5% (387/2877) had a history of diabetes and 1.9% (56/2877) died in hospital. After adjustment for confounders, patients with diabetes had a 2-fold increase in the hazard of mortality as compared to patients without diabetes (adjusted HR 2.11, 95%CI: 1.16-3.83, P=0.014). The on-admission glucose (per mmol/L≥4mmol/L) was significantly associated with subsequent mortality on COVID-19 (adjusted HR 1.17, 95%CI: 1.10-1.24, P<0.001).CONCLUSIONS Diabetes and on-admission glucose (per mmol/L≥4mmol/L) are associated with increased mortality in patients with COVID-19. These data support that blood glucose should be properly controlled for possibly better survival outcome in patients with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the National Health Commission of China and the Institutional Review Board at Huo Shen Shan Hospital (Wuhan, China). Written informed consent was waived by the Ethics Committee of the Huo Shen Shan Hospital for patients with emerging infectious diseases.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe would like to provide all data referred to the manuscript if they are requested.